Skip to content

UCB Ventures Principal

Steven Biesmans

Steven joined UCB Ventures in 2021 as Principal. He focuses on early-stage investment opportunities in next-generation therapeutics and breakthrough scientific innovations. Steven is Investor Director at ViaNautis and serves as Board Observer at SpliceBio, Walden Biosciences and EsoBiotec.

Prior to UCB Ventures, Steven spent 12 years working in preclinical drug discovery. He established novel technology platforms and managed scientific programs in pharma (UCB, Janssen R&D), biotech (StemoniX) and academic institutes (RWTH, BIOMED, Sanford Burnham Prebys) across Europe and the United States.

Steven holds a PhD in Neuroimmunology and a Master’s degree in Clinical Molecular Life Sciences from Hasselt University, and completed the Venture Capital Executive Program at the Wharton School (UPenn).

Back To Top